Roswell Park Awarded Nearly $2 Million to Study Cause of Racial Disparities in Breast Cancer
Share Article
A research team headed by Roswell Park Comprehensive Cancer Center epidemiologist Zhihong Gong, PhD, has been awarded a five-year, $1.9 million grant from the National Cancer Institute for an investigation into the role that certain genetic molecules play in the disparities seen between Black people and white people with breast cancer.
Roswell Park epidemiologist Dr. Zhihong Gong
Our study is novel and addresses an understudied area in breast cancer research among this underserved population with the worst prognosis. BUFFALO, N.Y. (PRWEB) February 17, 2021 A research team headed by Roswell Park Comprehensive Cancer Center epidemiologist Zhihong Gong, PhD, has been awarded a five-year, $1.9 million grant from the National Cancer Institute for an investigation into the role that certain genetic molecules pla
Study: Screen surgery patients for frailty
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Roswell Park Awarded Nearly $2 Million to Study Cause of Racial Disparities in Breast Cancer
thetelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thetelegraph.com Daily Mail and Mail on Sunday newspapers.
Exact Sciences to Acquire Ashion Analytics and Enter Research Collaboration with City of Hope s Genomics Institute, TGen
Provides Access to Industry-Leading Sequencing Lab and Plans for 10-Year Partnership with National Cancer Research Leaders
News provided by
Share this article
(PRNewsfoto/EXACT SCIENCES CORP)
(PRNewsfoto/EXACT SCIENCES CORP)
MADISON, Wis., Feb. 16, 2021 /PRNewswire/ Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has entered into an agreement to acquire Ashion Analytics, LLC (Ashion) from The Translational Genomics Research Institute (TGen), an affiliate of City of Hope. Ashion is a CLIA-certified and CAP-accredited sequencing lab based in Phoenix, Arizona with the genomics testing capabilities necessary to address the increasingly complex needs of clinical, academic, and biopharma customers focused on precision cancer treatments. The team at Ashion will help accelerate the development of Exact Sciences precision oncology portfolio, including
E-Mail
IMAGE: Sumanta Pal, MD, a SWOG Cancer Research Network researcher and City of Hope physician, led a study that sets a new standard of care for metastatic papillary kidney cancer view more
Credit: City of Hope
In a SWOG Cancer Research Network trial that put three targeted drugs to the test, the small molecule inhibitor cabozantinib was found most effective in treating patients with metastatic papillary kidney cancer - findings expected to change medical practice.
These findings will be presented at ASCO s virtual 2021 Genitourinary Cancers Symposium on Feb. 13, 2021 at 1 p.m. ET. The findings will be simultaneously published in